The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a new dual GIP and GLP-1 receptor that’s exhibiting significant potential in clinical trials for addressing obesity. Unlike some existing weight loss approaches, retatrutide appears to offer a greater substantial decrease in body size and enhance metabolic markers,